



Aldeyra Therapeutics to Host Conference Call and Webcast to Release Expanded Results from Allergen Chamber Trial and Announce Design of Phase 3 INVIGORATE Trial in Patients with Allergic Conjunctivitis

October 30, 2019

Event scheduled for 8:00 a.m. ET Thursday, October 31, 2019

LEXINGTON, Mass.--(BUSINESS WIRE)--Oct. 30, 2019-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call and webcast at 8:00 a.m. ET Thursday, October 31, 2019 to release expanded results from its allergen chamber clinical methods trial of topical ocular reproxalap in patients with allergic conjunctivitis and to announce the design of the Phase 3 INVIGORATE clinical trial.

The dial-in numbers are (866) 211-4098 for domestic callers and (647) 689-6613 for international callers. A live webcast of the conference call will also be available on the Investor Relations section of the Aldeyra Therapeutics website at <https://ir.aldeyra.com>.

After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for one year.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead investigational drug product candidates are first-in-class potential treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for retinal and systemic inflammatory diseases.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20191030006009/en/>

Source: Aldeyra Therapeutics, Inc.

Corporate Contact:

David McMullin
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218
dmcnullin@aldeyra.com

Investor & Media Contact:

Scott Solomon
Sharon Merrill Associates, Inc.
Tel: 617-542-5300
ALDX@investorrelations.com